checkAd
    Startseite > Aktien > Scilex Holding Company > Nachrichten
    Scilex Holding Company Aktie
    0,8255
     
    USD
    +8,91 %
    +0,0675 USD
    Letzter Kurs 21:02:14 Nasdaq
    0,8255
     
    USD
    300 STK
    Geldkurs 21:02:15
    0,8286
     
    USD
    500 STK
    Briefkurs 21:02:15
    ISIN: US80880W1062 · WKN: A3DW1Z · SYM: SCLX · USA

    Neueste Nachrichten

    Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine Prod
    14.05.24 · globenewswire · Scilex Holding Company
    Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
    13.05.24 · globenewswire · Scilex Holding Company
    Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering
    25.04.24 · globenewswire · Scilex Holding Company
    Scilex Holding Company Announces $15 Million Registered Direct Offering
    24.04.24 · globenewswire · Scilex Holding Company
    Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Adm
    16.04.24 · globenewswire · Scilex Holding Company
    Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
    09.04.24 · globenewswire · Scilex Holding Company
    Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
    27.03.24 · globenewswire · Scilex Holding Company
    Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
    21.03.24 · globenewswire · Scilex Holding Company
    Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
    20.03.24 · globenewswire · Scilex Holding Company
    Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchici
    20.03.24 · globenewswire · Scilex Holding Company
    Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
    19.03.24 · globenewswire · Scilex Holding Company
    Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB for Acute Treatment of Migraine With or Without Aura in Ca
    18.03.24 · globenewswire · Scilex Holding Company